FOLH1 and cancer: Studies with Telomelysin (OBP-301), a gene-modified oncolytic adenovirus introducing human telomerase reverse transcriptase (hTERT) promoter in cancer cells, and INO-5401, a combination of three separate DNA plasmids targeting Wilms tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) genes, are ongoing.